Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
- Sponsor
- Klaus Herfarth, MD
- Study ID
- NCT00509184
- Phase
- PHASE2
- Status
- Completed
Conditions
- Lymphoma, Malignant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG375 mg/m\^2, weekly (4 weeks), repeated after 4 weeks gap
Study Details
Combination of involved field radiotherapy for the control of macroscopic disease and CD20 antibody Rituximab for the control of microscopic remainders in other regions in patients with early stage nodal follicular lymphoma /grade I or II). Evaluation of DFSl and toxicity.
Key Dates
- Start date
- Mar 31, 2008
- Status verified
- Jan 2020
- Primary completion
- Apr 30, 2013
- Completion
- Apr 30, 2013
Study Design
- Enrollment
- 85 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
progression free survival [ Time Frame: 2 years ]